NeuroScientific Biopharmaceuticals reported an 80% clinical response rate in a stem-cell therapy program for patients with Crohn’s disease [1].
The results provide early evidence for the efficacy of the company's StemSmart cell therapy, offering a potential new avenue for treating a chronic inflammatory bowel disease that often resists standard medical interventions.
The Australian company conducted the program with a small group of five patients [1]. According to the report published Tuesday, all five participants showed some level of improvement following the treatment [1].
While all patients responded positively, the 80% clinical response rate refers to the proportion of patients who met specific primary efficacy markers [1]. The company developed the StemSmart therapy to target the underlying causes of Crohn's disease, a condition characterized by inflammation of the digestive tract.
NeuroScientific Biopharmaceuticals is based in Australia [1]. The company said the data demonstrates how its proprietary cell therapy interacts with the diseased tissue to reduce inflammation and promote healing [1].
Because the trial involved only five individuals, the data represents a preliminary stage of clinical research. Larger trials are typically required to establish a statistically significant result and to determine the long-term safety of the treatment before it can be approved for wider public use [1].
“NeuroScientific Biopharmaceuticals reported an 80% clinical response rate”
These results are an early-stage signal of efficacy, but the extremely small sample size of five patients means the findings are not yet statistically robust. In the pharmaceutical industry, such 'proof-of-concept' data is used to justify larger, more expensive Phase II and III trials to prove the treatment is safe and effective across a diverse population.
